6535 Stock Overview
A clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lumosa Therapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$358.00 |
| 52 Week High | NT$400.00 |
| 52 Week Low | NT$61.40 |
| Beta | 0.36 |
| 11 Month Change | 10.84% |
| 3 Month Change | 39.84% |
| 1 Year Change | 478.35% |
| 33 Year Change | 789.44% |
| 5 Year Change | 956.05% |
| Change since IPO | 602.10% |
Recent News & Updates
Shareholder Returns
| 6535 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 8.5% | 0.6% | -0.8% |
| 1Y | 478.4% | 9.2% | 29.0% |
Return vs Industry: 6535 exceeded the TW Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: 6535 exceeded the TW Market which returned 29.2% over the past year.
Price Volatility
| 6535 volatility | |
|---|---|
| 6535 Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6535's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6535's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 47 | n/a | www.lumosa.com.tw |
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology.
Lumosa Therapeutics Co., Ltd. Fundamentals Summary
| 6535 fundamental statistics | |
|---|---|
| Market cap | NT$59.05b |
| Earnings (TTM) | -NT$388.79m |
| Revenue (TTM) | NT$37.82m |
1,561x
P/S Ratio-151.9x
P/E RatioIs 6535 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6535 income statement (TTM) | |
|---|---|
| Revenue | NT$37.82m |
| Cost of Revenue | NT$13.96m |
| Gross Profit | NT$23.85m |
| Other Expenses | NT$412.65m |
| Earnings | -NT$388.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.36 |
| Gross Margin | 63.08% |
| Net Profit Margin | -1,028.15% |
| Debt/Equity Ratio | 0% |
How did 6535 perform over the long term?
See historical performance and comparison